Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435203 | 0.87 | RAB9A (0.46) | ALDH1A1GAASMN1; SMN2KDM4ERAB9A | |
| SCHEMBL3551333 | 0.79 | ALDH1A1 (0.41) | ALDH1A1GAATP53RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL2077470 | 0.78 | ALDH1A1 (0.40) | ALDH1A1GAATP53RAB9AMEN1 | |
| SCHEMBL13634317 | 0.75 | ALDH1A1 (0.39) | ALDH1A1GAATP53RAB9AMEN1 | |
| SCHEMBL18674681 | 0.74 | RAB9A (0.39) | ALDH1A1GAASMN1; SMN2KDM4ETP53 | |
| SCHEMBL3436205 | 0.73 | PTGDR2 (0.38) | ALDH1A1GAATP53RAB9AMEN1 | |
| SCHEMBL3557687 | 0.72 | PTGDR2 (0.42) | ALDH1A1GAATP53RAB9AMEN1 | |
| SCHEMBL13924180 | 0.72 | ALDH1A1 (0.46) | ALDH1A1GAASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL18678204 | 0.70 | ALDH1A1 (0.42) | ALDH1A1GAASMN1; SMN2KDM4ETP53 | |
| SCHEMBL3550333 | 0.69 | MMP13 (0.50) | ALDH1A1SMN1; SMN2RAB9APTGER1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | ALDH1A1 975/4885GAA 3904/4885SMN1; SMN2 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.